Vir Biotechnology appoints Johanna Friedl-Naderer as EVP and COO

Vir Biotechnology, Inc.

Appointed Johanna Friedl-Naderer, age 54, as EVP and COO effective April 4, 2022.
She previously served as EVP and Chief Business Officer, Global since March 2022.
Prior to Vir, spent 20+ years at Biogen, most recently as President of Europe, Canada & Partner Markets.
Responsible for business development, finance, product development/regulatory, and corporate affairs.
Compensation has not yet been determined; will be disclosed in a future amendment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Johanna Friedl-Naderer

Executive Vice President and Chief Operating Officer

VIR · Vir Biotechnology, Inc.

Effective: 2022-04-04
Filed: April 7, 2022, 7:59 PM ET

Effective as of April 4, 2022, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Johanna Friedl-Naderer, age 54, to serve as Executive Vice President and Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Johanna Friedl-Naderer was appointed as Executive Vice President and Chief Operating Officer at Vir Biotechnology, Inc..

Action: appointed
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

Effective as of April 4, 2022, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Johanna Friedl-Naderer, age 54, to serve as Executive Vice President and Chief Operating Officer of the Company.

View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-098865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.